TCRT (STOCKS)
Alaunos Therapeutics, Inc. Common Stock
$2.850000
-0.040000 (-1.38%)
Prev close: $2.890000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Holger Weis
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $7.04M
- Employees
- 1
- P/E (TTM)
- -1.29
- P/B (TTM)
- 3.15
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
0
Strong Buy
0
Buy
3
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2023 (Q4)
|
$-4.90 | $-4.59 | -0.3100 | -6.75% |
|
Sep 2023 (Q3)
|
$-6.00 | $-5.36 | -0.6450 | -12.04% |
|
Jun 2023 (Q2)
|
$-6.00 | $-6.73 | +0.7320 | +10.87% |
|
Mar 2023 (Q1)
|
$-6.00 | $-6.38 | +0.3755 | +5.89% |
Financial Statements
| Revenues | $5.00K |
| Benefits Costs and Expenses | $0.00 |
| Costs And Expenses | $4.23M |
| Nonoperating Income/Loss | $49.00K |
| Operating Expenses | $4.23M |
| Research and Development | $1.36M |
| Other Operating Expenses | $2.87M |
| Operating Income/Loss | -$4.23M |
| Income/Loss From Continuing Operations After Tax | -$4.18M |
| Income/Loss From Continuing Operations Before Tax | $5.00K |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$4.18M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$4.18M |
| Net Income/Loss Available To Common Stockholders, Basic | -$4.28M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $106.00K |
| Preferred Stock Dividends And Other Adjustments | $106.00K |
| Basic Earnings Per Share | -$2.20 |
| Diluted Earnings Per Share | -$2.20 |
| Basic Average Shares | 1,948,357 |
| Diluted Average Shares | 1,948,357 |
| Assets | $2.97M |
| Current Assets | $1.99M |
| Accounts Receivable | $3.00K |
| Other Current Assets | $1.99M |
| Noncurrent Assets | $978.00K |
| Fixed Assets | $91.00K |
| Other Non-current Assets | $887.00K |
| Liabilities | $813.00K |
| Current Liabilities | $813.00K |
| Accounts Payable | $613.00K |
| Other Current Liabilities | $200.00K |
| Noncurrent Liabilities | $0.00 |
| Equity | $2.15M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $2.15M |
| Liabilities And Equity | $2.97M |
| Net Cash Flow From Operating Activities | -$2.87M |
| Net Cash Flow From Operating Activities, Continuing | -$2.87M |
| Net Cash Flow From Investing Activities | -$98.00K |
| Net Cash Flow From Investing Activities, Continuing | -$98.00K |
| Net Cash Flow From Financing Activities | $3.26M |
| Net Cash Flow From Financing Activities, Continuing | $3.26M |
| Net Cash Flow | $294.00K |
| Net Cash Flow, Continuing | $294.00K |
| Comprehensive Income/Loss | -$4.18M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$4.18M |
| Other Comprehensive Income/Loss | $0.00 |